Quick Takeaways
- GILEAD SCIENCES, INC. has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $878,927,708.
- Recent insider filing activity is available below.
- Info
- Portfolio
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
- Holders
Insider Trading & Ownership of GILEAD SCIENCES, INC.
- Location
- Foster City, CA
- Summary
- The estimated value of insider holdings of GILEAD SCIENCES, INC. is at least $878,927,708 dollars as of 17 Feb 2026. GILEAD SCIENCES, INC. is the 10%+ Owner of Arcellx, Inc. and owns shares of Arcellx, Inc. (ACLX) stock worth about $371.44M. GILEAD SCIENCES, INC. is the 10%+ Owner of Arcus Biosciences, Inc. and owns shares of Arcus Biosciences, Inc. (RCUS) stock worth about $345.67M. GILEAD SCIENCES, INC. is the 10%+ Owner of ASSEMBLY BIOSCIENCES, INC. and owns shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) stock worth about $100.29M. GILEAD SCIENCES, INC. is the 10%+ Owner of Xilio Therapeutics, Inc. and owns shares of Xilio Therapeutics, Inc. (XLO) stock worth about $21.6M. GILEAD SCIENCES, INC. is the 10%+ Owner of LEAP THERAPEUTICS, INC. and owns shares of CYPHERPUNK TECHNOLOGIES INC. (CYPH) stock worth about $15.16M. GILEAD SCIENCES, INC. is the 10%+ Owner of HOOKIPA Pharma Inc. and owns shares of HOOKIPA Pharma Inc. (HOOK) stock worth about $13.6M. GILEAD SCIENCES, INC. is the 10%+ Owner of Allovir, Inc. and owns shares of Kalaris Therapeutics, Inc. (KLRS) stock worth about $11.16M.
- Signature
- Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow GILEAD SCIENCES, INC. and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Arcellx, Inc. ($371,444,668).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of GILEAD SCIENCES, INC.
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | 10%+ Owner | $371,444,668 | 28 Dec 2023 | ||
| RCUS | Arcus Biosciences, Inc. | 10%+ Owner | $345,672,360 | 18 Feb 2025 | ||
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 10%+ Owner | $100,290,003 | 08 Aug 2025 | ||
| XLO | Xilio Therapeutics, Inc. | 10%+ Owner | $21,601,543 | +$1,999,991 | +10% | 13 Feb 2026 |
| CYPH | LEAP THERAPEUTICS, INC. | 10%+ Owner | $15,159,572 | 10 Apr 2024 | ||
| HOOK | HOOKIPA Pharma Inc. | 10%+ Owner | $13,600,612 | 20 Dec 2023 | ||
| KLRS | Allovir, Inc. | 10%+ Owner | $11,158,950 | 27 Jun 2023 | ||
| KYTX | Kyverna Therapeutics, Inc. | 10%+ Owner | 12 Feb 2024 |
Insider Transactions Reported by GILEAD SCIENCES, INC.:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.